Literature DB >> 31595865

In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

Till F Omansen1,2, Renee A Marcsisin2, Brendon Y Chua2, Weiguang Zeng2, David C Jackson2, Jessica L Porter2, Ymkje Stienstra1, Tjip S van der Werf3,1, Timothy P Stinear2.   

Abstract

Buruli ulcer (BU) is a neglected tropical disease caused by infection with Mycobacterium ulcerans. Unclear transmission, no available vaccine, and suboptimal treatment regimens hamper the control of this disease. Carefully designed preclinical research is needed to address these shortcomings. In vivo imaging (IVIS®, Perkin Elmer, Waltham, MA) of infection is an emerging tool that permits monitoring of disease progression and reduces the need to using large numbers of mice at different time-points during the experiment, as individual mice can be imaged at multiple time-points. We aimed to further describe the use of in vivo imaging (IVIS) in BU. We studied the detection of M. ulcerans in experimentally infected BALB/c mouse tails and the subsequent histopathology and immune response in this pilot study. IVIS-monitoring was performed weekly in ten infected BALB/c mice to measure light emitted as a proxy for bacterial load. Nine of 10 (90%) BALB/c mice infected subcutaneously with 3.3 × 105 M. ulcerans JKD8049 (containing pMV306 hsp16+luxG13) exhibited light emission from the site of infection, indicating M. ulcerans growth in vivo, whereas only five of 10 (50%) animals developed clinical signs of the disease. Specific antibody titers were detected within 2 weeks of the infection. Interferon (IFN)-γ and interleukin (IL)-10 were elevated in animals with pathology. Histopathology revealed clusters of acid-fast bacilli in the subcutaneous tissue, with macrophage infiltration and granuloma formation resembling human BU. Our study successfully showed the utility of M. ulcerans IVIS monitoring and lays a foundation for further research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31595865      PMCID: PMC6896889          DOI: 10.4269/ajtmh.18-0959

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  62 in total

Review 1.  Buruli ulcer.

Authors:  Thorbjorg Einarsdottir; Kris Huygen
Journal:  Hum Vaccin       Date:  2011-11-01

2.  Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.

Authors:  H Dega; J Robert; P Bonnafous; V Jarlier; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

3.  Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.

Authors:  Herve Dega; Abdelhalim Bentoucha; Jerome Robert; Vincent Jarlier; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

4.  Aquatic insects as a vector for Mycobacterium ulcerans.

Authors:  Laurent Marsollier; Raymond Robert; Jacques Aubry; Jean-Paul Saint André; Henri Kouakou; Pierre Legras; Anne-Lise Manceau; Chetaou Mahaza; Bernard Carbonnelle
Journal:  Appl Environ Microbiol       Date:  2002-09       Impact factor: 4.792

5.  Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.

Authors:  S Klis; R A Kingma; W Tuah; T S van der Werf; Y Stienstra
Journal:  Trop Med Int Health       Date:  2016-07-26       Impact factor: 2.622

6.  Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans.

Authors:  Timothy P Stinear; Armand Mve-Obiang; Pamela L C Small; Wafa Frigui; Melinda J Pryor; Roland Brosch; Grant A Jenkin; Paul D R Johnson; John K Davies; Richard E Lee; Sarojini Adusumilli; Thierry Garnier; Stephen F Haydock; Peter F Leadlay; Stewart T Cole
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-21       Impact factor: 11.205

7.  Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease.

Authors:  Richard Phillips; Fred S Sarfo; Laure Guenin-Macé; Jérémie Decalf; Mark Wansbrough-Jones; Matthew L Albert; Caroline Demangel
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

8.  Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial.

Authors:  Akpeedje C Wadagni; Yves T Barogui; Roch C Johnson; Ghislain E Sopoh; Dissou Affolabi; Tjip S van der Werf; Janine de Zeeuw; Johanneke Kleinnijenhuis; Ymkje Stienstra
Journal:  Lancet Infect Dis       Date:  2018-04-05       Impact factor: 25.071

9.  Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase.

Authors:  Nuria Andreu; Andrea Zelmer; Samantha L Sampson; Melanie Ikeh; Gregory J Bancroft; Ulrich E Schaible; Siouxsie Wiles; Brian D Robertson
Journal:  J Antimicrob Chemother       Date:  2013-04-30       Impact factor: 5.790

10.  Persisting social participation restrictions among former Buruli ulcer patients in Ghana and Benin.

Authors:  Janine de Zeeuw; Till F Omansen; Marlies Douwstra; Yves T Barogui; Chantal Agossadou; Ghislain E Sopoh; Richard O Phillips; Christian Johnson; K Mohammed Abass; Paul Saunderson; Pieter U Dijkstra; Tjip S van der Werf; Ymkje Stienstra; Ymkje Stientstra
Journal:  PLoS Negl Trop Dis       Date:  2014-11-13
View more
  5 in total

1.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

2.  High antibody titres induced by protein subunit vaccines using Mycobacterium ulcerans antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice.

Authors:  Kirstie M Mangas; Nicholas J Tobias; Estelle Marion; Jérémie Babonneau; Laurent Marsollier; Jessica L Porter; Sacha J Pidot; Chinn Yi Wong; David C Jackson; Brendon Y Chua; Timothy P Stinear
Journal:  PeerJ       Date:  2020-08-07       Impact factor: 2.984

3.  Spatiotemporal analysis of mycolactone distribution in vivo reveals partial diffusion in the central nervous system.

Authors:  Emma Colucci-Guyon; Aline Rifflet; Sarah Saint-Auret; Anaëlle da Costa; Laurent Boucontet; Thomas Laval; Christophe Prehaud; Nicolas Blanchard; Jean-Pierre Levraud; Ivo G Boneca; Caroline Demangel; Laure Guenin-Macé
Journal:  PLoS Negl Trop Dis       Date:  2020-12-02

4.  Arabinogalactan enhances Mycobacterium marinum virulence by suppressing host innate immune responses.

Authors:  Ye-Yu Li; Han-Mei Liu; Decheng Wang; Yan Lu; Cairong Ding; Li-Shuang Zhou; Xiang-Yang Wu; Zi-Wei Zhou; Shu-Qin Xu; Chen Lin; Lian-Hua Qin; Yao Li; Jun Liu; Hai-Peng Liu; Lu Zhang
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

5.  In vivo imaging of transgenic Brugia malayi.

Authors:  Canhui Liu; Sai Lata De; Kristi Miley; Thomas R Unnasch
Journal:  PLoS Negl Trop Dis       Date:  2020-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.